ArticleInvestigational new drugs2026

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.

Takafumi Koyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.